HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gillette presents hair care, body wash

This article was originally published in The Rose Sheet

Executive Summary

Following announcement that Gillette Fusion is 24 Procter & Gamble brand to reach one-billion-dollar sales mark, Gillette expands male grooming line to include Gillette Hair Care and Gillette Body Wash, "designed to transform the shower experience," according to July 11 release. Gillette Hair Care line for men comprises six shampoos - specially formulated "to bond to and remove dirt and oil, leaving a man's hair incredibly clean" - and one conditioner; products retail for $4.49 apiece. At $4.29 apiece, Gillette 2 in 1 Body Washes "offer strong performance for superior cleansing" in three variants: Gillette Oil Control Face + Body Wash, Gillette Dry Skin Hydrator + Body Wash, and Gillette Gentle Clean Shampoo + Body Wash. Each body wash boasts unique dual-phase technology that keeps hydrators and cleansers in separate internal compartments within same bottle until combined in the shower "for a rich lather that leaves skin feeling moisturized long after the shower"...

You may also be interested in...



Gillette Hair-Care Entry Backed By Technology-Focused Ads; P&G Reports Q4

Gillette is supporting the launch of its new hair-care and body wash ranges - its most significant line extensions in 16 years - with a comprehensive media campaign promoting the brand's "expanded reach to the shower.

EMA Set To Discuss Safety Of Ranitidine Drugs Soon

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

Coronavirus Update: Supercomputing, Regulatory Flexibilities & Coordinating Supply Strategies

In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.

UsernamePublicRestriction

Register

RS015538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel